NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

SNGX

Soligenix Inc

Apr 17 • 04:00PM ET

2.10

Dollar change +0.04
Percentage change 1.94	%

Healthcare • Biotechnology • USA • NASD

Peers: TGTX MDGL AKBA BCRX TNXP AVIR KPTI APT ONCT FENC

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.19	Insider Own	0.03%	Shs Outstand	3.16M	Perf Week	11.11%
Market Cap	6.63M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.15M	Perf Month	-9.87%
Income	-8.27M	PEG	-	EPS next Q	-	Inst Own	0.97%	Short Float	1.48%	Perf Quarter	-7.49%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-50.69%	Short Ratio	0.52	Perf Half Y	-41.67%
Book/sh	1.64	P/B	1.28	EPS next Y	-	ROA	-88.11%	Short Interest	0.05M	Perf Year	-72.19%
Cash/sh	2.48	P/C	0.85	EPS next 5Y	-	ROE	-248.97%	52W Range	1.68 - 14.83	Perf YTD	-22.08%
Dividend Est.	-	P/FCF	-	EPS past 5Y	46.71%	ROI	-200.74%	52W High	-85.84%	Beta	1.99
Dividend TTM	-	Quick Ratio	1.80	Sales past 5Y	82.27%	Gross Margin	-	52W Low	25.00%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	1.80	EPS Y/Y TTM	57.83%	Oper. Margin	-	RSI (14)	48.56	Volatility	10.63% 7.91%
Employees	16	Debt/Eq	0.36	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	10.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	57.66%	Payout	-	Rel Volume	0.34	Prev Close	2.06
Sales Surprise	0.00%	EPS Surprise	-18.95%	Sales Q/Q	-	Earnings	Mar 21 BMO	Avg Volume	90.02K	Price	2.10
SMA20	-0.44%	SMA50	-6.29%	SMA200	-36.74%	Trades		Volume	30,362	Change	1.94%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-28-20	Downgrade	Dawson James	Buy → Neutral
Jan-31-18	Downgrade	H.C. Wainwright	Buy → Neutral	$5.50 → $2.70
Aug-14-17	Reiterated	Maxim Group	Buy	$4 → $5
Jul-17-17	Initiated	H.C. Wainwright	Buy	$11

Apr-14-25 07:30AM	Positive Outcome in 75% of CTCL Patients Treated with HyBryte for 18 Weeks (PR Newswire) -9.89%
Mar-25-25 08:30AM	IBN Initiates Coverage of Soligenix Inc. (GlobeNewswire)
07:30AM	Soligenix Announces Publication Demonstrating CiVax Booster Induces Rapid Broad Protection Against COVID-19 Variants (PR Newswire)
Mar-21-25 07:30AM	Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results (PR Newswire)
Mar-06-25 07:30AM	HyBryte Treatment Studies Presented at Two Medical Conferences in March (PR Newswire)
07:30AM	Loading…
Feb-04-25 07:30AM	Soligenix to Present at BIO CEO & Investor Conference (PR Newswire)
Jan-16-25 07:30AM	Soligenix to Present at Upcoming Investor Conferences (PR Newswire)
Jan-14-25 07:30AM	HyBryte Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma (PR Newswire) -15.97%
07:15AM	EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year (Benzinga)
Dec-17-24 10:24AM	Soligenix begins enrolling subjects in cutaneous T-cell lymphoma treatment trial (Clinical Trials Arena)
07:35AM	Soligenix initiates confirmatory Phase 3 trial of HyBryte (TipRanks)
Dec-16-24 07:30AM	Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
07:15AM	EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer (Benzinga)
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESSWIRE)
Dec-02-24 07:30AM	HyBryte Clinical Results Demonstrate Continued Improvement Post-Treatment (PR Newswire)
07:00AM	Loading…
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESSWIRE)
Nov-19-24 07:30AM	Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma (PR Newswire)
Nov-15-24 07:30AM	Soligenix to Present at November 21st Virtual Investor Summit Microcap Event (ACCESSWIRE)
Nov-14-24 07:15AM	Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels (Benzinga)
07:15AM	Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behet's Disease (PR Newswire)
Nov-08-24 07:30AM	Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results (PR Newswire)
Oct-29-24 07:30AM	Soligenix Announces Participation at the Spartan Capital Investor Conference (NewMediaWire)
Oct-24-24 07:30AM	Soligenix, Inc. to Present at the 2024 ThinkEquity Conference (GlobeNewswire)
Oct-22-24 07:30AM	Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin (PR Newswire)
Oct-16-24 07:30AM	Soligenix Invited to Present at Upcoming Investor Conferences (PR Newswire)
Oct-07-24 07:30AM	HyBryte Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference (PR Newswire) +9.30%
Oct-03-24 07:30AM	Soligenix Announces Partnership with Sterling Pharma Solutions (PR Newswire) -18.89%
Sep-20-24 09:00AM	Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Sep-16-24 07:30AM	Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024 (PR Newswire)
Sep-11-24 01:00PM	Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing (ACCESSWIRE)
07:30AM	Loading…
Sep-03-24 07:30AM	Soligenix Receives European Patent for Improved Production of Synthetic Hypericin (PR Newswire) +8.86%
Aug-16-24 09:00AM	Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) +13.77%
Aug-09-24 07:30AM	Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results (PR Newswire)
Aug-01-24 09:00AM	Strong Clinical Momentum for Soligenix's HyBryte in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone (GlobeNewswire)
Jul-31-24 09:53AM	7 Top Stocks Under $10: July 2024 Edition (InvestorPlace)
Jul-15-24 10:16AM	PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte Lighting the Way Towards Commercial Success with Promising FLASH Study Results (GlobeNewswire) -7.67%
Jul-10-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jul-09-24 02:37PM	5 Investors Betting Big on Soligenix (SNGX) Stock (InvestorPlace) +271.00%
10:04AM	Why Is Soligenix (SNGX) Stock Up 296% Today? (InvestorPlace)
07:30AM	Expanded HyBryte Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma (PR Newswire)
Jun-25-24 07:30AM	Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte Against Valchlor in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire) -21.60%
Jun-14-24 07:30AM	A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference (PR Newswire)
Jun-07-24 09:00AM	Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) -8.92%
Jun-05-24 08:00AM	Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte Replication Trial (GlobeNewswire)
May-31-24 07:30AM	Soligenix Announces Reverse Stock Split (PR Newswire) -10.00%
May-29-24 07:30AM	Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting (PR Newswire)
May-24-24 07:30AM	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting (PR Newswire)
May-23-24 07:30AM	Soligenix Encourages Stockholders to Vote 'FOR' Reverse Stock Split (PR Newswire) -8.65%
May-21-24 12:35PM	PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon (GlobeNewswire)
07:30AM	SuVax and MarVax Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference (PR Newswire)
May-20-24 07:30AM	Soligenix Encourages Stockholders to Vote Prior to Annual Meeting (PR Newswire)
May-16-24 07:30AM	Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice (PR Newswire) +7.29%
May-13-24 10:54AM	SNGX Stock Earnings: Soligenix Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-10-24 07:30AM	Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results (PR Newswire)
May-06-24 07:30AM	Soligenix to Present at Upcoming Conferences (PR Newswire)
Apr-25-24 07:30AM	Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa (PR Newswire) +11.49%
Apr-18-24 08:30AM	Soligenix Announces Pricing of $4.75 Million Public Offering (PR Newswire) -14.65%
Apr-15-24 03:55PM	Why Is Penny Stock Soligenix Trading Higher On Monday? (Benzinga) +21.73%
11:18AM	Why Is Soligenix (SNGX) Stock Up 58% Today? (InvestorPlace)
07:30AM	FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection (PR Newswire)
Apr-11-24 07:30AM	FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection (PR Newswire) -16.05%
Apr-03-24 07:30AM	Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte With the European Medicines Agency (PR Newswire) -10.15%
Mar-15-24 01:53PM	SNGX Stock Earnings: Soligenix Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
07:30AM	Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results (PR Newswire)
Feb-08-24 07:30AM	Soligenix Announces Formation of Behet's Disease Medical Advisory Board (PR Newswire) +5.54%
Jan-26-24 09:00AM	Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jan-25-24 07:30AM	Soligenix to Present at The Microcap Conference (PR Newswire)
Jan-08-24 07:30AM	FDA Grants Soligenix 'Fast Track' Designation for Dusquetide in the Treatment of Oral Lesions of Behet's Disease (PR Newswire) +16.68%
Jan-04-24 07:30AM	Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis (PR Newswire)
Jan-02-24 07:30AM	Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses (PR Newswire) +12.26%
Dec-01-23 07:30AM	'HyBryte Use in Early-Stage Cutaneous T-Cell Lymphoma' Published in Frontiers in Drug Discovery (PR Newswire) -25.53%
Nov-30-23 11:07AM	Why Is Soligenix (SNGX) Stock Up 285% Today? (InvestorPlace) +135.97%
07:30AM	Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behet's Disease (PR Newswire)
Nov-17-23 04:00PM	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting (PR Newswire) +7.61%
Nov-13-23 08:12AM	Soligenix Q3 Loss Narrows (RTT News)
07:30AM	Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results (PR Newswire)
Oct-20-23 04:00PM	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting (PR Newswire)
09:00AM	ASP Isotopes and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Oct-16-23 07:30AM	Soligenix to Present at The ThinkEquity Conference (PR Newswire)
Oct-13-23 09:00AM	SPI Energy and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Oct-06-23 09:00AM	Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Sep-25-23 07:30AM	Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures (PR Newswire)
Sep-22-23 04:00PM	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders (PR Newswire) +5.58%
Aug-24-23 05:30AM	SNGX: HyBryte Expanded Treatment Trial Underway (Zacks)
Aug-21-23 07:30AM	Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results (PR Newswire)
Aug-11-23 10:05AM	BioVie and Soligenix Interviews to Air on the RedChip Money Report(R) on Bloomberg TV (ACCESSWIRE)
Aug-10-23 07:30AM	HyBryte Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment (PR Newswire)
Jul-19-23 07:13AM	SNGX: Expanding SGX302 Phase 2a Study in Psoriasis (Zacks)
Jul-11-23 07:30AM	Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis (PR Newswire)
Jun-29-23 08:07AM	Soligenix, Inc. CEO is Featured in an Interview with SmallCaps Daily (NewMediaWire)
Jun-02-23 09:00AM	Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R) (ACCESSWIRE)
May-30-23 05:00AM	SNGX: Positive Results for Compatibility Study of HyBryte in CTCL (Zacks Small Cap Research)
May-16-23 07:30AM	Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis (PR Newswire) -6.02%
May-15-23 07:30AM	Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results (PR Newswire) +6.85%
May-11-23 07:30AM	Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire) -5.68%
May-09-23 04:05PM	Soligenix Announces Closing of $8.5 Million Public Offering (PR Newswire) -12.57% -10.22%
May-05-23 09:05AM	Soligenix Announces Pricing of $8.5 Million Public Offering (PR Newswire) -51.75%
May-04-23 03:54PM	Why Are Soligenix Shares Trading Higher Today (Benzinga) +60.56%
07:30AM	Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
May-03-23 07:30AM	Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors (PR Newswire) -11.26%

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNGX

Soligenix Inc

Upgrade your FINVIZ experience